GLP-1 for Dogs and Cats: What the Research Actually Shows

The commercial interest in a GLP-1 for dogs and cats is driven by a simple epidemiological fact: most pets in developed countries carry excess weight. The Association for Pet Obesity Prevention's 2022 United States survey, in which veterinary professionals assessed body condition directly rather than relying on owner opinion, found that 61% of cats and 59% of dogs were classified as overweight or obese.

The same survey exposed a perception gap that matters clinically. Roughly one third of owners whose pets had been assessed as overweight or obese by a veterinarian believed their animal had a normal or ideal body condition. Only about half of owners reported that a veterinary professional discussed body condition with them yearly. In other words, the problem is both widespread and widely unrecognized at home.

Excess weight is not a cosmetic issue in companion animals. In cats, obesity is the single most important modifiable risk factor for diabetes mellitus, and the 2025 iCatCare consensus guidelines treat weight management as central to both prevention and remission. Overweight cats are also predisposed to lower urinary tract disease, osteoarthritis, and reduced grooming ability. In dogs, excess weight aggravates orthopedic disease and shortens lifespan, though the link to diabetes is weaker because canine diabetes has a different mechanism entirely.

Here is the structural problem that drug developers are trying to solve. Weight loss in pets depends on owner behavior: measured portions, treat discipline, and multi-month consistency, often in multi-pet households where food cannot easily be separated. Prescription weight-loss diets work when followed, and they frequently are not. A long-acting injectable or implantable appetite-modulating agent is attractive precisely because it removes daily owner compliance from the equation. That is the commercial logic, and it is worth stating plainly before looking at the evidence, because logic is not data.

This article is educational and does not replace veterinary advice. It contains no amounts, no schedules, and no administration instructions of any kind.

No. As of November 2026, there is no GLP-1 receptor agonist approved for dogs or cats by the FDA, the EMA, or any other regulator. If you searched for "is there GLP 1 for dogs" or "semaglutide for cats" and landed on a page offering a product, you are looking at either a human drug being repurposed without veterinary data or an unregulated research chemical.

What does exist is a small, genuinely active development pipeline, all of it aimed at cats rather than dogs:

• OKV-119 (Okava Pharmaceuticals), a removable subcutaneous implant releasing exenatide over months. Its MEOW-1 field study in client-owned overweight and obese cats began dosing in December 2025 under an FDA Center for Veterinary Medicine Investigational New Animal Drug (INAD) application. Okava has publicly stated it aims to request FDA approval in 2027 or 2028.
• AKS-562c (Akston Biosciences), an investigational once-weekly GLP-1 Fc-fusion protein. A Cornell University veterinary trial in client-owned cats with excess body condition, led by Patrick Carney, DVM, PhD, was announced in late 2025. No efficacy data have been presented.

Two things follow from this. First, an INAD application is a permission to study, not a finding of safety or effectiveness. It means the FDA has allowed controlled investigational use under supervision. It does not mean the product works, and it does not mean it will be approved. Many veterinary candidates fail at this stage.

Second, the absence of any dog-directed GLP-1 program is not an oversight. It reflects species biology, which we cover below. Developers are concentrating on cats because feline metabolic disease is the better-matched target.

If you want the human-side background on how this drug class works, our guide to GLP-1 receptor agonists covers the receptor pharmacology, and incretins and next-generation GLP-1 compounds explains where the field is heading in people. Neither should be read as applicable to pets.

OKV-119 is an investigational, miniature subcutaneous implant designed to deliver exenatide, a 39 amino acid GLP-1 receptor agonist originally derived from a peptide found in the Gila monster, over a period of months from a single placement during a routine veterinary visit.

The first feline report appeared in 2021. Klotsman and colleagues published a brief research report in Frontiers in Veterinary Science describing safety and tolerability of OKV-119 implants in a small group of 4 healthy cats over 62 days, alongside a 42-day proof-of-concept phase measuring weekly plasma exenatide concentrations and body weight. The implants were easily identified on radiographs and were tolerated without apparent implant site reactions. The authors highlighted a design feature that matters for a feline product: because the implant can be removed, drug exposure can be stopped immediately if an animal loses too much weight or tolerates the drug poorly. That is not possible with an injected long-acting depot.

The second report, published in BMC Veterinary Research in May 2024 by Klotsman, Anderson and Gilor and funded by Okava, characterized the release profile. Five purpose-bred neutered male cats received a single implant configured to release exenatide for up to 84 days and were followed for a 112-day study period. Over the first 28 days, reduced caloric intake and body weight reduction were observed in four of five cats, and in those cats a body weight reduction of at least 5% was maintained throughout the 112 days. The authors concluded that plasma exenatide concentrations in roughly the 1.5 to 4 ng/mL range appeared sufficient to induce weight loss in cats.

These are the honest limits of that evidence: five purpose-bred laboratory cats, a manufacturer-funded release-profile study, and no control group. It establishes that the delivery system works mechanically and that exenatide exposure in cats is associated with reduced intake. It does not establish clinical benefit, long-term safety, or effect size in the client-owned pets that would actually receive it. That is precisely what MEOW-1 is designed to test, in roughly 50 cats over a three-month primary period with an optional extension. No MEOW-1 results have been published or presented as of November 2026.

Exenatide is the only GLP-1 receptor agonist with a meaningful peer-reviewed feline literature, and it predates the current pet GLP-1 hype by a decade. Four studies are worth knowing.

Healthy cats (2015). Rudinsky, Adin, Borin-Crivellenti, Gilor and colleagues published the pharmacology of extended-release exenatide in six healthy cats in Domestic Animal Endocrinology, following drug concentrations for 12 weeks after a single subcutaneous administration. Hyperglycemic clamps performed before and after showed increased insulin release and decreased glucagon release. The conclusion was that extended-release exenatide is safe in healthy cats and stimulates insulin secretion, acting broadly as it does in people.

Obese non-diabetic cats (2016). Hoelmkjaer and colleagues ran a 12-week, double-blinded, placebo-controlled study of short-acting exenatide in 12 obese but otherwise healthy client-owned cats, published in PLOS ONE. The primary endpoint was insulin concentration. Exenatide tended to reduce body weight under continued normal feeding, but body composition measured by dual-energy x-ray absorptiometry and adipokine levels were unaffected. For an obesity indication, that is a weak signal.

Newly diagnosed diabetic cats (2016 and 2020). Riederer, Zini and colleagues published a placebo-controlled trial of extended-release exenatide in 30 cats with newly diagnosed diabetes mellitus in the Journal of Veterinary Internal Medicine, in which all cats also received insulin glargine and a low-carbohydrate diet. Krämer, Riederer, Fracassi and colleagues later analyzed glycemic variability from those same blood glucose curves at 1, 3, 6, 10 and 16 weeks, concluding that the combination of extended-release exenatide, insulin and a low-carbohydrate diet might be advantageous in newly diagnosed diabetic cats.

Maintaining remission (2025). The most rigorous feline study to date. Gilor, Fleeman and colleagues randomized 22 client-owned cats in recent diabetic remission to monthly extended-release exenatide or saline for two years or until relapse. Thirteen cats completed the two years without relapse; nine exited prematurely (placebo n = 4, exenatide n = 5). There was no difference in remission duration between groups (placebo median 669 days, range 121 to 721; exenatide 662 days, range 28 to 735; p = 0.9). The authors reported that extended-release exenatide contributed to maintenance of glycemic control as reflected by hemoglobin A1c, but did not affect remission duration.

Read together: exenatide is pharmacologically active in cats, it is reasonably well tolerated in controlled settings, and on the hardest clinical endpoint tested so far it did not change the outcome that mattered.

This is the question behind most of the search traffic, and the answer is unambiguous. There is no published clinical trial and no published pharmacokinetic study of semaglutide or tirzepatide in cats or dogs. Not a field study, not a laboratory pharmacokinetic characterization, not a case series. Reviews of companion animal obesity drug development, including the 2024 review by Zomer and Cooke in Biology and the 2025 comparative review by Kim and Yun in Pharmaceutics, discuss these molecules only by extrapolation from human and rodent work.

That matters more than it may sound. Semaglutide's long human half-life depends on albumin binding through a fatty acid side chain, and tirzepatide acts at two receptors. Neither property transfers predictably across species. Protein binding, renal and hepatic handling, receptor distribution, and gastrointestinal sensitivity all differ between humans, cats and dogs. Without species pharmacokinetics, nobody knows how long a given exposure persists in a 4 kg cat, and that is the one number that determines whether an adverse effect lasts hours or weeks.

The one other GLP-1 analog with real feline data is liraglutide. Hall, Adin, Borin-Crivellenti and colleagues published its pharmacokinetics and pharmacodynamics in healthy cats in Domestic Animal Endocrinology in 2015. Liraglutide improved glycemic control during induced hyperglycemia by increasing insulin and decreasing glucagon concentrations, with a pharmacokinetic profile broadly similar to that reported in people. Notably, appetite reduction and decreased body weight of 9% plus or minus 3% occurred in all cats studied. That is a substantial, uniform effect, and in a species prone to hepatic complications from not eating, uniform appetite suppression is a safety consideration as much as an efficacy one.

No comparable liraglutide study exists in dogs. Older experimental canine work using GLP-1 and analogs such as lixisenatide and exenatide was designed to study hepatic glucose metabolism or to model human pre-diabetes, not to develop a canine product. Those studies used purpose-bred laboratory dogs and do not support clinical use in pets.

For context on how these molecules behave in the species they were actually developed for, see our monographs on semaglutide and tirzepatide.

The reason every pet GLP-1 program targets cats is that feline and canine diabetes are different diseases, and only one of them has the biology that incretin drugs need.

Diabetes in cats closely resembles human type 2 diabetes. The dominant features are insulin resistance, often driven by obesity, combined with progressive beta cell dysfunction, with islet amyloid deposition commonly described. Crucially, many newly diagnosed diabetic cats retain functional beta cells, which is why feline diabetic remission is a real and relatively common clinical goal: with prompt glycemic control, weight management and a low-carbohydrate diet, a proportion of cats stop requiring insulin. The 2025 iCatCare consensus guidelines devote substantial attention to predicting, achieving and prolonging remission.

Diabetes in dogs is typically insulin-deficient. The usual pathways are immune-mediated or otherwise progressive beta cell destruction, pancreatitis, or diestrus-associated and other hormonal insulin resistance in intact females. By the time a dog is diagnosed, beta cell mass is generally too depleted to recover. Canine diabetic remission is not a realistic therapeutic target, and lifelong insulin is the standard of care.

GLP-1 receptor agonists act largely by amplifying glucose-dependent insulin secretion from beta cells, suppressing glucagon, slowing gastric emptying and reducing food intake. The insulinotropic arm of that mechanism requires beta cells that can still respond. In a dog with minimal residual beta cell function, the glucose-lowering rationale largely collapses, leaving only the appetite and gastric effects. This is also why early experimental work in insulin-dependent diabetic dogs failed to show the kind of insulin-like metabolic effects seen in other models.

Could a GLP-1 still be useful in dogs purely for weight loss, independent of diabetes? In principle yes, and that is exactly why it would need its own canine safety and efficacy program. Dogs are prone to pancreatitis, a condition in which GLP-1 drugs have been scrutinized even in humans. No such canine program has published data. Anyone offering a GLP-1 "for dogs" today is operating entirely outside the evidence base.

This is the most important section of this article, because a predictable pattern is already visible. The ASPCA has issued a pet safety alert on rising GLP-1 exposures in pets, noting that as more households keep semaglutide, tirzepatide, liraglutide or dulaglutide on hand, accidental and intentional pet exposures have increased. The signs most commonly reported in exposed animals are vomiting, diarrhea, lethargy and decreased appetite.

Several factors compound in a small animal:

• Scale mismatch. Human injection devices are engineered for adults weighing 60 to 120 kg. A domestic cat typically weighs 4 to 6 kg. Devices of this kind are not designed to deliver the fractional quantities a cat would require, and attempting to split them introduces measurement error on top of an already unknown target.
• No species pharmacokinetics. Because semaglutide and tirzepatide have never been characterized in cats or dogs, nobody can predict how long an exposure lasts. A long-acting human formulation, once injected, cannot be retrieved. This is the explicit safety argument the OKV-119 researchers made for a removable implant.
• Dehydration and aspiration. Prolonged vomiting in a small animal produces clinically significant fluid and electrolyte loss far faster than in a person, and vomiting pets are at risk of aspiration.
• Hepatic lipidosis in cats. A cat that stops eating for several days can develop hepatic lipidosis, a serious and potentially fatal condition. Appetite suppression is not a benign side effect in this species, and the liraglutide study found appetite reduction in every cat tested.
• Hypoglycemia. A diabetic pet already receiving insulin that is suddenly given an agent reducing food intake and glucagon output can become dangerously hypoglycemic.
• Pancreatitis concern. Pancreatitis is a recognized topic of pharmacovigilance for this class in humans and is common in both dogs and cats. There are no feline or canine safety data to characterize this risk.

Our article on GLP-1 side effects describes the gastrointestinal profile documented in human trials, where patients can report symptoms, stop the drug, and access intravenous fluids. A cat can do none of those things.

If your pet has licked, chewed, or been injected with a human GLP-1 product, contact your veterinarian or an emergency veterinary service immediately. In the United States, the ASPCA Animal Poison Control Center is reachable at 888-426-4435. Bring the device or packaging with you.

If your cat or dog has been diagnosed with diabetes, there are approved products, and none of them are peptides apart from insulin itself.

Insulin remains the foundation of therapy in both species and the only option for dogs. Several veterinary insulin products are authorized in the United States and the European Union, and the choice, monitoring strategy and diet are decisions only your veterinarian can make.

For cats, two oral SGLT2 inhibitors have been approved since 2022. These are small molecules, not peptides, and they work in an entirely different way from GLP-1 agonists: they block glucose reabsorption in the kidney so that excess glucose is excreted in urine.

Approval does not mean risk-free. The FDA has issued a Dear Veterinarian Letter on important safety conditions associated with Bexacat, and the EMA has issued a Direct Healthcare Professional Communication on the known risk of diabetic ketoacidosis in cats treated with Senvelgo. Both products have specific restrictions on which cats are eligible, particularly regarding prior insulin treatment, and both require veterinary monitoring. The FDA's own owner-facing page comparing the two drugs is a useful starting point for a conversation with your vet.

For canine obesity specifically, it is worth noting that a weight-loss drug for dogs has existed before: dirlotapide, a first-in-class microsomal triglyceride transfer protein inhibitor, was approved by the FDA in January 2007. It was not a peptide and did not involve GLP-1 biology. Its history is a reminder that approval and long-term commercial availability are two different things.

If your pet is overweight, the evidence-based path in November 2026 has nothing to do with GLP-1 drugs. It involves an objective body condition assessment, a calculated energy target, a measured feeding plan, treat accounting, and recheck weigh-ins every two to four weeks. This is unglamorous and it works when it is actually followed.

Useful questions to raise at the appointment:

• What is my pet's body condition score, and what is a realistic target weight?
• What daily energy intake should we aim for, and does that include treats and any food from other household members?
• Should we screen for conditions that affect weight, such as hypothyroidism in dogs or early diabetes in cats?
• If my cat is diabetic, is remission a realistic goal, and does an SGLT2 inhibitor or insulin fit this case better?
• Are there any veterinary clinical trials recruiting locally that my pet might be eligible for?

That last point is the only legitimate route to a GLP-1 for a pet today. Investigational products such as OKV-119 and AKS-562c are available exclusively through supervised studies, with informed consent, defined monitoring, and a veterinarian responsible for the animal. That is a fundamentally different proposition from an owner injecting a human product at home.

Two free tools on this site may help you follow through on a plan your veterinarian has already set. The calorie calculator for dogs and cats estimates daily energy requirements so you can translate a target into actual portions. For households already managing veterinary-prescribed insulin at home, the U-40 and U-100 insulin syringe unit converter helps avoid the unit-marking confusion that causes real harm when the wrong syringe type is used with a given insulin concentration. Neither tool recommends a quantity of any medication, and neither substitutes for your veterinarian's written instructions.

Medical disclaimer: this article is for educational purposes only. It does not provide veterinary advice and deliberately contains no administration instructions. No GLP-1 receptor agonist is approved for use in dogs or cats. Never give a human medication to an animal without explicit instruction from a licensed veterinarian who has examined that animal. Regulatory status and the availability of investigational products vary by jurisdiction and change over time.